Evidence map›Paper›PMID 41462410›Full record

ArticleJournal of the Chinese Medical Association : JCMA2026

Adjuvant chemoradiotherapy for stage III gastric cancer: A differential role in R0 and non-R0 resection.

Yin-Che Wang, Nai-Jung Chiang, Yi-Ping Hung, I-Chun Lai, Shih-Chieh Lin, Anna Fen-Yau Li, Hung-Yuan Yu, Yee Chao, Ching-Yun Kung, Kuo-Hung Huang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yin-Che WangDivision of Hematology and Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ROC.ORCID 0000-0002-1325-1891
Nai-Jung ChiangSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yi-Ping HungSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
I-Chun LaiSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Shih-Chieh LinDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Anna Fen-Yau LiSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Hung-Yuan YuSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yee ChaoSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Ching-Yun KungSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Kuo-Hung HuangSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Wen-Liang FangSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Ming-Huang ChenSchool of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.ORCID 0000-0003-3187-7393

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of adjuvant concurrent chemoradiotherapy (CCRT) in stage III gastric cancer remains unclear, particularly after D2 lymphadenectomy. While CCRT may benefit patients with residual disease, its value for patients with R0 resection remains uncertain. Accordingly, this study evaluated the survival effect of adjuvant CCRT in R0 and non-R0 resection groups.

methodsWe retrospectively reviewed the medical records of patients with stage III gastric adenocarcinoma who underwent gastrectomy with D2 lymphadenectomy between January 2011 and June 2024. Patients were stratified by resection margin (R0 vs non-R0) and receipt of adjuvant therapy. Propensity score matching (PSM) was performed to adjust for baseline imbalances. Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression analyses.

resultsA total of 559 patients were included, of whom 483 (86.4%) underwent R0 resection and 76 (13.6%) underwent non-R0 resection. Overall, 78.9% received adjuvant therapy, with CCRT more frequently used in the non-R0 group (28.9% vs 4.6%; p < 0.001). In the non-R0 resection group, both adjuvant chemotherapy and CCRT were associated with significantly improved OS, with CCRT demonstrating additional benefits over chemotherapy ( p = 0.039). After PSM, CCRT was associated with a nonsignificant trend toward improved OS (34.2 vs 28.4 months, hazard ratio: 0.55, 95% confidence interval: 0.26-1.15; p = 0.096) compared with chemotherapy. In matched patients with R0 resection, no survival benefit was observed with CCRT (24.1 vs 36.0 months, hazard ratio: 1.29, 95% confidence interval: 0.56-2.98; p = 0.550).

conclusionAdjuvant CCRT was associated with a trend toward improved survival in patients with non-R0 resection. However, it was not associated with additional survival benefits compared with chemotherapy in patients undergoing R0 resection after D2 lymphadenectomy, indicating that systemic therapy alone may be sufficient. These findings support the selective use of CCRT and underscore the need for prospective studies to optimize adjuvant strategies.

Indexed as

Chemoradiotherapy, AdjuvantStomach NeoplasmsAdultAgedFemaleGastrectomyHumansLymph Node ExcisionMaleMiddle AgedNeoplasm StagingRetrospective StudiesChemoradiotherapyGastrectomyGastric cancerSurvival

Identifiers

PMID41462410
PMCPMC12900180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.